Fig. 2
From: Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
Cytokine concentration during the treatment course and at the time of neutropenia. Post-C4 levels are not displayed as the patient was admitted two weeks after C3, i.e., prior to C4 sample collection. Compared to baseline, a significant rise in IL-6, IL-10 and IL-17 are seen at the point of irAE. These co-relate with rise in CRP (Fig. 1). Two weeks post irAE, IL-6 and IL-17 levels demonstrate a downtrend while IL-10 level was noted to be rising. Sample collection at neutropenia was a day after treatment with steroids. Hence the treatment effect cannot be entirely excluded.